Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1992 May;30(5):1170–1173. doi: 10.1128/jcm.30.5.1170-1173.1992

Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.

M E Erwin 1, R N Jones 1
PMCID: PMC265244  PMID: 1316366

Abstract

CI-960, fleroxacin, lomefloxacin, and temafloxacin were tested against over 100 strains of Neisseria gonorrhoeae. Each organism was tested in triplicate by using agar dilution and disk diffusion methods recommended by the National Committee for Clinical Laboratory Standards. CI-960 was the most potent compound, with a MIC against 90% of the strains tested of 0.008 microgram/ml, and the least active was fleroxacin (MIC against 90% of strains, 0.12 microgram/ml). Only the susceptible interpretive category was recommended for the CI-960 tests as follows: 5-micrograms disk, greater than or equal to 39 mm (MIC correlate, less than or equal to 0.12 microgram/ml). Three interpretive categories were proposed for the other fluoroquinolones as follows: fleroxacin, 5-micrograms disk susceptible at greater than or equal to 33 mm (MIC correlate, less than or equal to 0.25 microgram/ml), intermediate at 28 to 32 mm (MIC correlate, 0.5 microgram/ml), and resistant at less than or equal to 27 mm (MIC correlate, greater than 0.5 microgram/ml); lomefloxacin, 10-micrograms disk susceptible at greater than or equal to 35 mm (MIC correlate, less than or equal to 0.12 microgram/ml), intermediate at 28 to 34 mm (MIC correlates, 0.25 to 0.5 microgram/ml), and resistant at less than or equal to 27 mm (MIC correlate, greater than 0.5 microgram/ml); and temafloxacin, 5-micrograms disk susceptible at greater than or equal to 36 mm (MIC correlate, less than or equal to 0.06 microgram/ml), intermediate at 28 to 35 mm (MIC correlates 0.12 to 0.25 microgram/ml), and resistant at less than or equal to 27 mm (greater than 0.25 microgram/ml). Interpretive agreement between disk diffusion results and the MICs was 100% for each agent, with the exception of lomefloxacin, which had a 0.9% minor error. All drugs were stable in GC agar medium for at least 21 days when stored at 2 to 5 degrees C.

Full text

PDF
1170

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett M. S., Jones R. N., Erwin M. E., Johnson D. M., Briggs B. M. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):389–401. doi: 10.1016/0732-8893(91)90066-o. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N. Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests. J Clin Microbiol. 1989 Dec;27(12):2861–2863. doi: 10.1128/jcm.27.12.2861-2863.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crider S. R., Colby S. D., Miller L. K., Harrison W. O., Kerbs S. B., Berg S. W. Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N Engl J Med. 1984 Jul 19;311(3):137–140. doi: 10.1056/NEJM198407193110301. [DOI] [PubMed] [Google Scholar]
  4. Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A., 2nd Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol. 1991 Oct;29(10):2111–2114. doi: 10.1128/jcm.29.10.2111-2114.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fuchs P. C., Jones R. N., Barry A. L., Ayers L. W., Gavan T. L., Gerlach E. H., Thornsberry C. RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria. Diagn Microbiol Infect Dis. 1987 May;7(1):29–35. doi: 10.1016/0732-8893(87)90066-6. [DOI] [PubMed] [Google Scholar]
  6. Gransden W. R., Warren C. A., Phillips I., Hodges M., Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet. 1990 Jan 6;335(8680):51–51. doi: 10.1016/0140-6736(90)90177-7. [DOI] [PubMed] [Google Scholar]
  7. Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hirai K., Aoyama H., Hosaka M., Oomori Y., Niwata Y., Suzue S., Irikura T. In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother. 1986 Jun;29(6):1059–1066. doi: 10.1128/aac.29.6.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hirose T., Okezaki E., Kato H., Ito Y., Inoue M., Mitsuhashi S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother. 1987 Jun;31(6):854–859. doi: 10.1128/aac.31.6.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jephcott A. E., Turner A. Ciprofloxacin resistance in gonococci. Lancet. 1990 Jan 20;335(8682):165–165. doi: 10.1016/0140-6736(90)90035-4. [DOI] [PubMed] [Google Scholar]
  11. Jones R. N., Aldridge K. E., Barry A. L., Fuchs P. C., Gerlach E. H., Pfaller M. A., Washington J. A., 2nd Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing. Diagn Microbiol Infect Dis. 1988 Aug;10(4):221–240. doi: 10.1016/0732-8893(88)90094-6. [DOI] [PubMed] [Google Scholar]
  12. Jones R. N., Fuchs P. C., Washington J. A., 2nd, Gavan T. L., Murray P. R., Gerlach E. H., Thornsberry C. Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae. Diagn Microbiol Infect Dis. 1990 Nov-Dec;13(6):499–507. doi: 10.1016/0732-8893(90)90082-7. [DOI] [PubMed] [Google Scholar]
  13. Jones R. N., Gavan T. L., Thornsberry C., Fuchs P. C., Gerlach E. H., Knapp J. S., Murray P., Washington J. A., 2nd Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol. 1989 Dec;27(12):2758–2766. doi: 10.1128/jcm.27.12.2758-2766.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lassus A., Renkonen O. V., Ellmén J. Fleroxacin versus standard therapy in gonococcal urethritis. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):223–225. doi: 10.1093/jac/22.supplement_d.223. [DOI] [PubMed] [Google Scholar]
  15. Lim K. B., Rajan V. S., Giam Y. C., Lui E. O., Sng E. H., Yeo K. L. Treatment of uncomplicated gonorrhoea with rosoxacin (acrosoxacin). Br J Vener Dis. 1984 Jun;60(3):157–160. doi: 10.1136/sti.60.3.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Loo P. S., Ridgway G. L., Oriel J. D. Single dose ciprofloxacin for treating gonococcal infections in men. Genitourin Med. 1985 Oct;61(5):302–305. doi: 10.1136/sti.61.5.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Morrison P. J., Mant T. G., Norman G. T., Robinson J., Kunka R. L. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrob Agents Chemother. 1988 Oct;32(10):1503–1507. doi: 10.1128/aac.32.10.1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Putnam S. D., Lavin B. S., Stone J. R., Oldfield E. C., 3rd, Hooper D. G. Evaluation of the standardized disk diffusion and agar dilution antibiotic susceptibility test methods by using strains of Neisseria gonorrhoeae from the United States and Southeast Asia. J Clin Microbiol. 1992 Apr;30(4):974–980. doi: 10.1128/jcm.30.4.974-980.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wagenvoort J. H., van der Willigen A. H., van Noort J. A. Decreased sensitivity of Neisseria gonorrhoeae to quinolone compounds. Eur J Clin Microbiol. 1986 Dec;5(6):685–685. doi: 10.1007/BF02013305. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES